分子靶向治疗在复发性上皮性卵巢癌中的研究进展  

Progress of molecular targeted therapy in the treatment for recurrent epithelial ovarian cancer

作　　者：张秦[1] 钱敏[1] 管群[1] 刘琦[1] 

机构地区：[1]南京军区南京总医院妇产科,南京医学硕士210002

出　　处：《医学研究生学报》2016年第10期1116-1120,共5页Journal of Medical Postgraduates

摘　　要：上皮性卵巢癌是目前致死率最高的妇科恶性肿瘤,绝大多数患者在接受反复化疗后将出现耐药,而二线化疗方法仅对少数患者有效,因此,临床上急需探索疗效好且毒副作用较小的治疗药物。近年来,靶向药物在复发性上皮性卵巢癌的临床试验中取得了较好的结果,如贝伐单抗、奥拉帕尼、帊唑帕尼等都可延长铂耐药卵巢癌患者的无进展生存时间,为复发性卵巢癌患者带来新的治疗策略。文中针对靶向治疗在复发性上皮性卵巢癌的治疗现状及进展进行综述。Epithelial ovarian cancer is the most lethal gynecologic malignancy, drug-resistance will eventually appear after repeated intermittent chemotherapy. However, second-line chemotherapy only works on a few patients, new drugs with better efficacy and less side effects are needed. There are a number of promising results of molecular targeted therapy in recent clinical trials for patients with recurrent epithelial ovarian cancer, such as Bevacizumab, Olaparib, Pazopanib, etc. They have been demonstrated to improve progression-free survival of patients with platinum-resistant ovarian cancer, which might become a new strategy for such patients. In this review, we summarized the current status and progress of targeted therapy for recurrent epithelial ovarian cancer.

关 键 词：分子靶向治疗 上皮性卵巢癌 复发 

分 类 号：R737.31[医药卫生—肿瘤]